Corbus Pharmaceuticals Holding (CRBP)

Currency in USD
8.6700
+0.2400(+2.85%)
Closed·
8.8400+0.1700(+1.96%)
·
CRBP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CRBP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.55008.9700
52 wk Range
4.640061.8900
Key Statistics
Prev. Close
8.67
Open
8.59
Day's Range
8.55-8.97
52 wk Range
4.64-61.89
Volume
71.76K
Average Volume (3m)
151.59K
1-Year Change
-84.67%
Book Value / Share
9.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CRBP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
42.2222
Upside
+386.99%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Corbus Pharmaceuticals Holding Company Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Holding SWOT Analysis


Promising Pipeline
Explore Corbus Pharmaceuticals' diverse portfolio, featuring potential best-in-class therapies for cancer and obesity, positioning the company for significant market impact
Financial Fortitude
Delve into Corbus's robust financial position, with $120.1 million in cash reserves providing runway for key development milestones and future growth
Market Opportunity
Learn how Corbus targets lucrative markets in oncology and obesity, with analysts projecting billion-dollar sales potential for lead candidates
Analyst Outlook
Discover the bullish sentiment among analysts, with price targets ranging from $77 to $85, reflecting confidence in Corbus's innovative approach and market potential
Read full SWOT analysis

Compare CRBP to Peers and Sector

Metrics to compare
CRBP
Peers
Sector
Relationship
P/E Ratio
−1.8x−3.0x−0.5x
PEG Ratio
−0.440.010.00
Price/Book
1.0x2.6x2.6x
Price / LTM Sales
-8.2x3.3x
Upside (Analyst Target)
374.5%208.2%42.9%
Fair Value Upside
Unlock10.3%6.2%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 42.2222
(+386.99% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
-1.44 / -1.23
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CRBP Income Statement

People Also Watch

45.920
ASTS
-1.52%
139.78
CRWV
+7.90%
17.370
QBTS
+2.78%
71.86
OKLO
-4.59%

FAQ

What Stock Exchange Does Corbus Pharmaceuticals Holding Trade On?

Corbus Pharmaceuticals Holding is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Corbus Pharmaceuticals Holding?

The stock symbol for Corbus Pharmaceuticals Holding is "CRBP."

What Is the Corbus Pharmaceuticals Holding Market Cap?

As of today, Corbus Pharmaceuticals Holding market cap is 106.25M.

What Is Corbus Pharmaceuticals Holding's Earnings Per Share (TTM)?

The Corbus Pharmaceuticals Holding EPS (TTM) is -4.76.

From a Technical Analysis Perspective, Is CRBP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Corbus Pharmaceuticals Holding Stock Split?

Corbus Pharmaceuticals Holding has split 1 times.

How Many Employees Does Corbus Pharmaceuticals Holding Have?

Corbus Pharmaceuticals Holding has 28 employees.

What is the current trading status of Corbus Pharmaceuticals Holding (CRBP)?

As of 12 Aug 2025, Corbus Pharmaceuticals Holding (CRBP) is trading at a price of 8.67, with a previous close of 8.67. The stock has fluctuated within a day range of 8.55 to 8.97, while its 52-week range spans from 4.64 to 61.89.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.